[go: up one dir, main page]

SK502001A3 - Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions - Google Patents

Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions Download PDF

Info

Publication number
SK502001A3
SK502001A3 SK50-2001A SK502001A SK502001A3 SK 502001 A3 SK502001 A3 SK 502001A3 SK 502001 A SK502001 A SK 502001A SK 502001 A3 SK502001 A3 SK 502001A3
Authority
SK
Slovakia
Prior art keywords
acid
methyl
phenyl
biphenyl
hydroxy
Prior art date
Application number
SK50-2001A
Other languages
English (en)
Slovak (sk)
Inventor
Thomas Michael Andrew Bocan
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of SK502001A3 publication Critical patent/SK502001A3/sk

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Indole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Furan Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Quinoline Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
SK50-2001A 1998-07-21 1999-06-18 Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions SK502001A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9363998P 1998-07-21 1998-07-21
PCT/US1999/013948 WO2000004892A2 (en) 1998-07-21 1999-06-18 Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions

Publications (1)

Publication Number Publication Date
SK502001A3 true SK502001A3 (en) 2002-06-04

Family

ID=22239992

Family Applications (1)

Application Number Title Priority Date Filing Date
SK50-2001A SK502001A3 (en) 1998-07-21 1999-06-18 Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions

Country Status (25)

Country Link
EP (1) EP1098662A2 (is)
JP (1) JP2002521328A (is)
KR (1) KR20010083134A (is)
CN (1) CN1310629A (is)
AP (1) AP2001002035A0 (is)
AU (1) AU4701799A (is)
BG (1) BG105162A (is)
BR (1) BR9912296A (is)
CA (1) CA2335062A1 (is)
CZ (1) CZ2001126A3 (is)
EA (1) EA200100153A1 (is)
EE (1) EE200100046A (is)
HR (1) HRP20010055A2 (is)
HU (1) HUP0102880A3 (is)
ID (1) ID30030A (is)
IL (1) IL140982A0 (is)
IS (1) IS5809A (is)
NO (1) NO20010291L (is)
OA (1) OA11584A (is)
PL (1) PL346011A1 (is)
SK (1) SK502001A3 (is)
TR (1) TR200100205T2 (is)
WO (1) WO2000004892A2 (is)
YU (1) YU3501A (is)
ZA (1) ZA200100294B (is)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1414848A (zh) * 1999-11-05 2003-04-30 沃尼尔·朗伯公司 Acat抑制剂对斑块破裂的预防
CO5261615A1 (es) 1999-12-01 2003-03-31 Agouron Pharma Compuestos, composiciones y metodos para estimular el crecimiento y elongacion de neuronas
JP2003534239A (ja) * 1999-12-17 2003-11-18 ヴァージコア・インコーポレーテッド 新規なスクシナート化合物、組成物、並びに使用及び調製方法
MXPA03001857A (es) * 2000-09-01 2003-06-04 Sankyo Co Composicones medicinales.
GB0100761D0 (en) 2001-01-11 2001-02-21 Biocompatibles Ltd Drug delivery from stents
DE60321775D1 (de) * 2002-04-03 2008-08-07 Topotarget Uk Ltd Carbaminsäurederivate enthaltend eine piperazin verknüpfung als hdac-inhibitoren
KR101011373B1 (ko) * 2002-07-11 2011-01-28 비큐론 파마슈티컬스 인코포레이티드 항균작용을 갖는 n-히드록시아미드 유도체
WO2011092284A1 (en) * 2010-01-29 2011-08-04 Euroscreen S.A. Novel amino acid derivatives and their use as gpr43 receptor modulators
CN104211695B (zh) * 2013-06-04 2017-04-12 中国医学科学院医药生物技术研究所 一组胺甲酰基苯磺酰类化合物的用途
US20180000817A1 (en) * 2015-01-15 2018-01-04 Biocant - Associação De Transferência De Tecnologia Treatment of hutchinson-gilford progeria syndrome and diseases related to vascular ageing
CN106831697B (zh) * 2017-03-15 2019-11-05 深圳市康道生物有限公司 川榛有效提取成分及其在防治动脉粥样硬化中的应用
WO2025224168A1 (en) 2024-04-24 2025-10-30 Idorsia Pharmaceuticals Ltd Aryl sulfone and sulfanone derivatives as orexin receptor modulators

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5366987A (en) * 1991-08-22 1994-11-22 Warner-Lambert Company Isoxazolyl-substituted alkyl amide ACAT inhibitors
US5491172A (en) * 1993-05-14 1996-02-13 Warner-Lambert Company N-acyl sulfamic acid esters (or thioesters), N-acyl sulfonamides, and N-sulfonyl carbamic acid esters (or thioesters) as hypercholesterolemic agents
CZ26198A3 (cs) * 1995-08-04 1998-07-15 Warner-Lambert Company Použití derivátů kyseliny amidosírové, acyl-sulfonamidů nebo sulfonyl-karbamatů pro výrobu léčiva s účinky snížení hladin lipoproteinů
ES2167733T3 (es) * 1996-05-17 2002-05-16 Warner Lambert Co Inhibidores de metaloproteinasa matricial de bifenilsulfonamida.
CA2256716A1 (en) * 1996-09-04 1998-03-12 Warner-Lambert Company Matrix metalloproteinase inhibitors and their therapeutic uses

Also Published As

Publication number Publication date
YU3501A (sh) 2005-06-10
ZA200100294B (en) 2002-01-10
OA11584A (en) 2004-07-20
AP2001002035A0 (en) 2001-03-31
NO20010291D0 (no) 2001-01-18
PL346011A1 (en) 2002-01-14
HRP20010055A2 (en) 2002-04-30
HUP0102880A2 (en) 2002-06-29
WO2000004892A2 (en) 2000-02-03
CZ2001126A3 (cs) 2002-01-16
CN1310629A (zh) 2001-08-29
WO2000004892A3 (en) 2000-05-18
EA200100153A1 (ru) 2001-08-27
IL140982A0 (en) 2002-02-10
EP1098662A2 (en) 2001-05-16
KR20010083134A (ko) 2001-08-31
JP2002521328A (ja) 2002-07-16
BR9912296A (pt) 2001-04-17
EE200100046A (et) 2002-06-17
ID30030A (id) 2001-11-01
AU4701799A (en) 2000-02-14
BG105162A (en) 2001-12-29
HUP0102880A3 (en) 2002-11-28
TR200100205T2 (tr) 2001-05-21
IS5809A (is) 2001-01-12
CA2335062A1 (en) 2000-02-03
NO20010291L (no) 2001-01-18

Similar Documents

Publication Publication Date Title
AU741768B2 (en) Method for treating and preventing heart failure and ventricular dilatation
AU737117B2 (en) Use of matrix metalloproteinase inhibitors for treating neurological disorders and promoting wound healing
US6133304A (en) ACE inhibitor-MMP inhibitor combinations
SK502001A3 (en) Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions
US20020049237A1 (en) Statin-MMP inhibitor combinations
KR20010041916A (ko) 스타틴-매트릭스 메탈로프로테이나제 저해제 복합제제
US20050020607A1 (en) Statin-MMP inhibitor combinations
MXPA01000780A (en) Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions
EP1366765A1 (en) Use of matrix metalloproteinase inhibitors for treating neurological disorders and promoting wound healing
HK1038317A (en) Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions
MXPA00003736A (en) Ace inhibitor-mmp inhibitor combinations